Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)
In the present application, we propose to refine and extend current insight into AAF mechanism and therapy by examining the importance of pharmacologic RAAS inhibition, ACE genotype, and their interaction in secondary AF prevention. We have 3 specific aims:
- To confirm that RAAS inhibition therapy reduces the incidence of AF recurrence.
- To test the hypothesis that the incidence of AF recurrence in the absence of RAAS inhibition therapy is higher among patients with the D allele.
- To explore the hypothesis that RAAS inhibition therapy is more effective for preventing AF recurrence in patients with the DD genotype than in those with DI or II genotypes.
|Atrial Fibrillation||Other: no drug Drug: start cozaar Drug: continue cozaar||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
|Official Title:||Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)|
- AF burden [ Time Frame: 1 year ]
|Study Start Date:||November 2005|
|Study Completion Date:||November 2007|
|Primary Completion Date:||November 2007 (Final data collection date for primary outcome measure)|
Experimental: A Group 1 no drug
Patients who have not taken ACE/ARB, randomized to no drug.
Other: no drug
none, no drug
Experimental: A Group 2
Patients who have not taken ACE/ARB, randomized to take cozaar.
Drug: start cozaar
Patients currently taking ACE/ARB will have their prescription changed to cozaar.
Drug: continue cozaar
Please refer to this study by its ClinicalTrials.gov identifier: NCT01233635
|United States, Pennsylvania|
|Pittsburgh, Pennsylvania, United States, 15213|